tiprankstipranks
Trending News
More News >
Amgen (AMGN)
NASDAQ:AMGN
Advertisement

Amgen (AMGN) AI Stock Analysis

Compare
6,637 Followers

Top Page

AMGN

Amgen

(NASDAQ:AMGN)

Select Model
Select Model
Select Model
Neutral 69 (OpenAI - 4o)
Rating:69Neutral
Price Target:
$306.00
▲(12.10% Upside)
Amgen's overall stock score reflects strong earnings performance and a solid valuation, balanced by technical indicators suggesting caution. The company's robust revenue growth and strategic focus on innovation are significant strengths, while high leverage and declining cash flow growth are key risks.
Positive Factors
Revenue Growth
Amgen's strong revenue and volume growth, driven by key product sales, underscores its robust market position and demand for its therapies.
R&D Pipeline Progress
Progress in R&D, particularly in late-stage programs, enhances Amgen's future growth potential and competitive edge in the biotech industry.
Biosimilars Contribution
Significant growth in biosimilar sales indicates Amgen's successful diversification and ability to capture market share in a competitive segment.
Negative Factors
High Leverage
Amgen's high leverage could pose financial risks, potentially impacting its ability to invest in growth opportunities and manage economic downturns.
Declining Cash Flow Growth
A decline in free cash flow growth may constrain Amgen's capacity to fund R&D and strategic initiatives, affecting long-term innovation and competitiveness.
Regulatory Challenges
Regulatory challenges, including drug pricing reforms, could pressure Amgen's pricing strategies and margins, impacting profitability over time.

Amgen (AMGN) vs. SPDR S&P 500 ETF (SPY)

Amgen Business Overview & Revenue Model

Company DescriptionAmgen Inc. is a leading biotechnology company based in the United States, focused on discovering, developing, manufacturing, and delivering innovative human therapeutics. Established in 1980, Amgen operates primarily in the biopharmaceutical sector, specializing in the areas of oncology, nephrology, rheumatology, and other serious diseases. The company is known for its core products including Enbrel, Neulasta, and Prolia, which are designed to treat a variety of medical conditions through advanced biotechnology techniques.
How the Company Makes MoneyAmgen generates revenue primarily through the sale of its biopharmaceutical products, which are marketed under its proprietary brand names. The company's revenue model is heavily reliant on its portfolio of biologic therapies that address critical health issues, leading to significant sales in both domestic and international markets. Key revenue streams include direct product sales, royalties from licensed products, and collaborations with other pharmaceutical companies that enhance its research and development efforts. Additionally, Amgen often engages in strategic partnerships to develop new therapies, which can further boost its earnings through shared research costs and potential profit-sharing agreements.

Amgen Key Performance Indicators (KPIs)

Any
Any
Product Sales by Geography
Product Sales by Geography
Highlights where Amgen's products are selling the most, indicating strong markets and potential areas for expansion or risk due to regional economic factors.
Chart InsightsAmgen's U.S. sales have shown strong growth, particularly in 2024 and 2025, reflecting the company's robust performance and strategic focus on key products like Repatha and EVENITY. The earnings call highlights a 9% revenue increase driven by a 13% volume growth, with significant contributions from the biosimilar and rare disease portfolios. Despite challenges like Prolia's sales decline and increased R&D expenses, Amgen's commitment to innovation and AI integration suggests continued momentum, especially in the U.S. market, which remains a vital growth driver.
Data provided by:Main Street Data

Amgen Earnings Call Summary

Earnings Call Date:Aug 05, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Nov 04, 2025
Earnings Call Sentiment Positive
Amgen's Q2 2025 earnings call highlighted strong revenue and volume growth, driven by significant increases in sales of key products and a robust rare disease portfolio. The company also demonstrated progress in its R&D pipeline. However, challenges remain with pricing pressures and regulatory changes. Despite these challenges, the positive aspects of the call outweigh the negatives.
Q2-2025 Updates
Positive Updates
Revenue and Volume Growth
Amgen reported a 9% increase in revenues year-over-year and a 13% increase in volume. 15 products delivered at least double-digit sales growth.
Notable Product Performance
Repatha sales increased by 31% to $696 million, and EVENITY sales grew by 32% to $518 million. UPLIZNA sales increased by 91% year-over-year to $176 million.
Strong Rare Disease Portfolio
The rare disease portfolio grew 19% year-over-year, delivering nearly $1.4 billion in sales.
Biosimilars Contribution
Biosimilar portfolio sales grew 40% year-over-year to $661 million.
R&D Pipeline Progress
Amgen advanced multiple late-stage programs, including MariTide for obesity, which showed up to 20% weight loss at 52 weeks in trials.
Negative Updates
Pricing Pressures
Prolia sales declined 4% year-over-year due to lower net selling price.
Challenges in Regulatory Environment
Ongoing challenges with drug pricing reforms and the shifting regulatory landscape, specifically in relation to Medicaid MFN clauses.
Competition in Oncology
Increased competition in the oncology market, specifically for biosimilar versions of OPDIVO and KEYTRUDA.
Company Guidance
In the second quarter of fiscal year 2025, Amgen reported robust financial performance, with revenues increasing by 9% year-over-year to $9.2 billion, driven by a 13% volume growth. The company highlighted strong sales growth across its portfolio, with 15 products achieving double-digit or better sales increases. Notably, Repatha sales rose 31% to $696 million, and EVENITY sales increased by 32% to $518 million. Meanwhile, the rare disease portfolio grew by 19% to $1.4 billion in sales, and the innovative oncology portfolio saw a 14% increase, generating $2.2 billion. The biosimilars portfolio also exhibited significant growth, with sales up 40% to $661 million. Amgen maintained its guidance for full-year 2025 revenues to be between $35 billion and $36 billion, with non-GAAP earnings per share projected to range from $20.20 to $21.30. The company underscored its ongoing investments in research and development, including MariTide and other late-stage pipeline programs, while managing operating expenses effectively.

Amgen Financial Statement Overview

Summary
Amgen shows strong profitability with steady revenue growth and healthy margins. However, high debt levels and declining free cash flow growth present potential risks. The company needs to manage its leverage and improve cash flow generation to maintain financial stability.
Income Statement
75
Positive
Amgen's income statement shows a solid performance with a steady revenue growth rate of 2.32% in the TTM period. The gross profit margin of 63% and net profit margin of 17.39% indicate strong profitability, although both have decreased compared to previous years. The EBIT and EBITDA margins remain healthy at 24.20% and 36.27% respectively, reflecting efficient operations. However, the slight decline in margins suggests rising costs or competitive pressures.
Balance Sheet
60
Neutral
The balance sheet reveals a high debt-to-equity ratio of 9.24, indicating significant leverage, which could pose financial risks if not managed carefully. The return on equity is robust at 92.94%, showcasing effective use of equity to generate profits. However, the equity ratio is relatively low, suggesting a heavy reliance on debt financing.
Cash Flow
70
Positive
Cash flow analysis shows a slight decline in free cash flow growth by -2.84% in the TTM period, which could be a concern if it continues. The operating cash flow to net income ratio of 0.53 and free cash flow to net income ratio of 0.90 indicate strong cash generation relative to net income, supporting the company's liquidity position.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue34.91B33.42B28.19B26.32B25.98B25.42B
Gross Profit22.50B20.57B19.77B19.92B19.52B19.27B
EBITDA15.90B13.36B14.80B12.17B11.30B13.00B
Net Income6.62B4.09B6.72B6.55B5.89B7.26B
Balance Sheet
Total Assets87.90B91.84B97.15B65.12B61.16B62.95B
Cash, Cash Equivalents and Short-Term Investments8.03B11.97B10.94B9.30B8.04B10.65B
Total Debt56.20B60.10B64.61B38.95B33.98B33.45B
Total Liabilities80.47B85.96B90.92B61.46B54.47B53.54B
Stockholders Equity7.43B5.88B6.23B3.66B6.70B9.41B
Cash Flow
Free Cash Flow10.61B10.39B7.36B8.79B8.38B9.89B
Operating Cash Flow12.01B11.49B8.47B9.72B9.26B10.50B
Investing Cash Flow-1.45B-1.05B-26.20B-6.04B733.00M-5.40B
Financing Cash Flow-11.84B-9.41B21.05B-4.04B-8.27B-4.87B

Amgen Technical Analysis

Technical Analysis Sentiment
Negative
Last Price272.98
Price Trends
50DMA
287.44
Negative
100DMA
284.91
Negative
200DMA
283.89
Negative
Market Momentum
MACD
-3.06
Positive
RSI
41.29
Neutral
STOCH
15.21
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AMGN, the sentiment is Negative. The current price of 272.98 is below the 20-day moving average (MA) of 279.29, below the 50-day MA of 287.44, and below the 200-day MA of 283.89, indicating a bearish trend. The MACD of -3.06 indicates Positive momentum. The RSI at 41.29 is Neutral, neither overbought nor oversold. The STOCH value of 15.21 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AMGN.

Amgen Risk Analysis

Amgen disclosed 29 risk factors in its most recent earnings report. Amgen reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Amgen Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
75
Outperform
$196.23B12.1133.49%4.12%2.00%20.01%
73
Outperform
$135.09B12.6412.10%7.20%14.72%
72
Outperform
$111.94B11.327.17%4.86%-9.32%120.62%
69
Neutral
$146.96B22.3399.14%3.43%13.10%110.67%
68
Neutral
$89.80B17.8028.96%5.58%2.57%
68
Neutral
$139.09B22.3032.08%2.80%3.69%501.26%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AMGN
Amgen
273.97
-37.81
-12.13%
BMY
Bristol-Myers Squibb
44.15
-5.26
-10.65%
GILD
Gilead Sciences
112.62
31.21
38.34%
MRK
Merck & Company
78.58
-30.92
-28.24%
PFE
Pfizer
23.85
-3.19
-11.80%
SNY
Sanofi
45.65
-10.20
-18.26%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 25, 2025